EUCTR2009-017918-69-SK进行中（未招募）1 期
A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit - Not applicable
AB Science0 个研究点目标入组 200 人开始时间: 2010年8月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient = 18 years old, male or female, weighting more than 40 kg
- •2.Patient with histologically or cytologically confirmed non-resectable or metastatic stage III (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage IV melanoma
- •3.Patient with detectable c-kit JM mutation confirmed by DNA or RNA sequencing, which is expected to be mainly found after screening of mucosal or acral melanoma or melanoma on skin with chronic sun-induced damages (defined by a microscopically marked elastosis involving the skin surrounding their primary melanoma)
- •4.Patient with measurable disease according to RECIST
- •5.Patient with ECOG = 2
- •6.Patient with life expectancy = 12 weeks
- •7.Patient with adequate organ function
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Haemoglobin = 10 g/dL
- •Platelets (PLT) = 100 x 109/L
- •AST/ALT = 2.5 x ULN (= 5 x ULN in case of liver metastases)
- •Bilirubin = 1.5 x ULN (= 3 x ULN in case of liver metastases)
- •Creatinine clearance = 50 mL/min (Cockcroft and Gault formula)
- •Albuminaemia = 0.75 x LLN
- •Urea = 2 x ULN
- •Proteinuria < 30 mg/dL on dipstick; in case of proteinuria = 30 mg/dL, 24-hour proteinuria = 1.5 g/24 h
- •8.Man or woman of child bearing potential, (entering the study after a menstrual period and who have a negative pregnancy test) must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for three months after the last treatment intake
- •9.Patient able and willing to comply with study procedures as per protocol
- •10.Patient able to understand, and willing to sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant, or nursing female patient
- •2.Patient with other malignancies from which the patient has been continuously disease-free for < 3 years, with the exception of melanoma, cervical carcinoma in situ, basal cell or squamous cell skin cancer, ductal or lobular carcinoma in situ of the breast
- •3.Patient with active brain metastases are not eligible. Patients with treated brain metastases are eligible if :
- •(a) presence of 3 brain lesions or less
- •(b) lesion(s) diameter is = 2 cm
- •(c) radiation therapy (gamma knife) was completed = 4 weeks prior to baseline
- •(d) surgery was completed =4 weeks prior to baseline
- •(e) lesions assessed by follow-up scan (or MRI if MRI performed before brain therapy) = 1 month after brain therapy are considered under control at baseline
- •4.Patient refractory to dacarbazine defined as patient presenting a disease progression after 3 months of dacarbazine therapy.
- •5.Prior treatment with a tyrosine kinase c-kit inhibitor
- •6.Patient with grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within six months before baseline)
- •7.Patient with clinically uncontrolled infectious diseases including HIV or AIDS-related illness
- •8.Major surgery or radiation therapy within four weeks of starting the study treatment
- •9.Patient with an history of poor compliance or an history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •10.Previous radiotherapy, chemotherapy and/or previous adjuvant therapy with interferon, vaccines or therapy with IL-2 or GM-CSF within 4 weeks prior to baseline. Those patients will require a four weeks wash-out period before baseline. Similarly, any previous treatment with an investigational agent will require a wash-out period of four weeks before baseline
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentEUCTR2008-000973-40-HUAB SCIENCE222
招募中
3 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentGISTNL-OMON44826AB Science20
暂停
不适用
A study to evaluate the efficacy and safety of Aceinavir combined with supportive Standard of Care (SoC) in hospitalized patients with moderate coronavirus disease (COVID-19)CTRI/2020/08/027284Dyuthi Biosciences Private Limited
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentGastro-intestinal stromal tumour (GIST)MedDRA version: 17.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000973-40-GRAB SCIENCE450
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentEUCTR2008-000973-40-ATAB SCIENCE450